Skip to main content

Table 6 Cost effectiveness analysis over 5-year treatment duration

From: The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia

Therapy

Cost/patient (US$)

QALYs gained/patient

ICER (ΔC/ΔE)

Comparator

Celecoxib + PPI

6,705.80

2.68

2,502.16

No treatment

Ibuprofen + PPI*

7,008.80

2.31

Dominated

-

Celecoxib*

7,407.10

2.50

Dominated

-

Diclofenac + PPI*

7,930.50

2.39

Dominated

-

Diclofenac*

10,140.20

2.05

Dominated

-

Ibuprofen*

10,586.10

1.83

Dominated

-

Etoricoxib + PPI

11,574.20

2.64

Dominated

-

Etoricoxib

12,983.90

2.48

Dominated

-

  1. *Simple dominance: Another option is less expensive and more effective
  2. ICER, incremental cost-effectiveness ratio; PPI, proton-pump inhibitor; QALY, quality-adjusted life year
  3. ICER: additional cost per patient achieving a unit of effectiveness compared with the next less costly, non-dominated option
Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us